Daptomycin

  Cat. No.:  DC1050   Featured
Chemical Structure
103060-53-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
Cas No.: 103060-53-3
Chemical Name: Daptomycin
Synonyms: Daptomycin;Daptomycin,N-(1-Oxodecyl)-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-threonylglycyl-L-ornithinyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-seryl-(3R)-3-methyl-L-α-glutamyl-α,2-diamino-γ-oxo-benzenebut;LY146032; Cidecin;Cubicin;CUBICIN DAPTOMYCIN;Daptomycin,N-(1-Oxodecyl)-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-threonylglycyl-L-ornithinyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-seryl-(3R)-3-methyl-L-α-glutamyl-α,2-diamino-γ-oxo-benzenebutanoicacid(13-4)lactone;LY-146032;1-Oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane,cyclic peptide deriv.;Benzenebutanoic acid, N-(1-oxodecyl)-L-tryptophyl-D-asparaginyl-L-a-aspartyl-L-threonylglycyl-L-ornithyl-L-a-aspartyl-D-alanyl-L-a-aspartylglycyl-D-seryl-(3R)-3-methyl-L-a-glutamyl-a,2-diamino-g-oxo-, (13®4)-lactone, (aS)-;Dapcin;Daptomicina;Daptomycine;Daptomycinum;Deptomycin;N-(1-Oxodecyl)-L-tryptophyl-D-asparaginyl-L-a-aspartyl-L-threonylglycyl-L-ornithyl-L-a-aspartyl-D-alanyl-L-a-aspartylglycyl-D-seryl-(3R)-3-methyl-L-a-glutamyl-(aS)-a,2-diamino-g-oxobenzenebutanoicacid (13®4)-lactone;Daptomycin (LY146032);Daptomycin Ready Made Solution;LY 146032;Daptomycin, >=99%;(3S)-3-[[(2S)-4-Amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]ami;Decanoyl-Trp-Asn-Asp-DL-Thr(1)-Gly-Orn-Asp-D-Ala-DL-Asp-Gly-D-Ser-Glu(3R-Me)-DL-Asp(Ph(2-NH2))-(1);Daptomycin-d5 Trifluoroacetic Acid Salt;decanoyl-DL-Trp-DL-Asn-DL-Asp-DL-xiThr(1)-Gly-DL-Orn-DL-Asp-DL-Ala-DL-Asp-Gly-DL-Ser-DL-Glu(3-Me)-DL;N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone;Q418747;Cubicin Rf;Daptomycine [French];SCHEMBL13491700;DAPZURA RT;EX-A1967;DAPTOMYCIN [VANDF];J01XX09;UNII-NWQ5N31VKK;MK-3009;DAPTOMYCIN [INN];NWQ5N31VKK;D01080;103060-53-3;N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone;Daptomycin in Sodium Chloride;DAPTOMYCIN [MI];DAPTOMYCIN [USAN];Daptomycin (JAN/USAN/INN);HY-B0108;N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine-epsilon1-lactone;Daptomycinum [Latin];DAPTOMYCIN [JAN];DB00080;Daptomycin for injection;N-(Decanoyl)-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-(3R)-3-methyl-L-glutamyl-3-(2-aminobenzoyl)-L-alanine 1.13->3.4-lactone;DAPTOMYCIN [MART.];D4229;Daptomycin [USAN:INN:BAN];DAPTOMYCIN [EMA EPAR];Daptomicina [Spanish];Cubicin (TN);DTXSID1041009;DAPTOMYCIN (MART.);DTXCID9021009;N-DECANOYL-L-TRYPTOPHYL-L-ASPARAGINYL-L-ASPARTYL-L-THREONYLGLYCYL-L-ORNITHYL-L-ASPARTYL-D-ALANYL-L-ASPARTYLGLYCYL-D-SERYL...
SMILES: O1C(C([H])(C([H])([H])C(C2=C([H])C([H])=C([H])C([H])=C2N([H])[H])=O)N([H])C(C([H])(C([H])(C([H])([H])[H])C([H])([H])C(=O)O[H])N([H])C(C([H])(C([H])([H])O[H])N([H])C(C([H])([H])N([H])C(C([H])(C([H])([H])C(=O)O[H])N([H])C(C([H])(C([H])([H])[H])N([H])C(C([H])(C([H])([H])C(=O)O[H])N([H])C(C([H])(C([H])([H])C([H])([H])C([H])([H])N([H])[H])N([H])C(C([H])([H])N([H])C(C([H])(C1([H])C([H])([H])[H])N([H])C(C([H])(C([H])([H])C(=O)O[H])N([H])C(C([H])(C([H])([H])C(N([H])[H])=O)N([H])C(C([H])(C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)N([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Formula: C72H101N17O26
M.Wt: 1620.6707
Purity: 99%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
In Vivo: At a dose of 10 mg/kg given twice daily, daptomycin reduces the number of organisms per kidney significantly compared with that in infected untreated controls within 48 h after the initiation of therapy. At 20 mg/kg given once a day, daptomycin is less effective but reduces colony counts significantly after 4 days of therapy, and its activity is comparable to that of vancomycin or vancomycin-gentamicin given twice daily[2].
In Vitro: Daptomycin has excellent in-vitro inhibitory and bactericidal activity against nafcillin-susceptible and resistant staphylococci (MIC90 less than or equal to 0.5 mg/L) and against enterococci (MIC90 less than or equal to 2.0 mg/L). Daptomycin is more active than vancomycin against the majority of isolated tested. With the exception of trimethoprim-sulphamethoxazole, daptomycin is the most active agent in vitro against enterococci, and is the most active against nafcillin-resistant staphylococci. Daptomycin and vancomycin show a marked increase in MIC when the inoculum is increased from 105 to 107 cfu/mL[1]. Daptomycin is effective within a very narrow range of drug concentrations (from 0.125 to 2.0 tLg/mL) and is more active than other agents tested against S. faecalis[2]. Daptomycin inhibits the formation of these nucleotide-linked intermediates[3].
Animal Administration: Inocula containing 109 CFU/mL are prepared from an 18-h brain heart infusion broth culture. The exact number in each inoculum is subsequently determined by the standard serial 10-fold dilution agar pour plate technique. Animals are challenged intravenously with a 1.0-mL inoculum. This inoculum is known to infect the renal medulla of normal rats. Twenty-four hours later the animals are divided into eight groups and are given either saline only (controls) or antibiotic therapy initiated with Daptomycin at 10 mg/kg (Daptomycin10), Daptomycin at 20 mg/kg (Daptomycin20), Daptomycin10 plus gentamicin at 1.5 mg/kg, vancomycin at 20 mg/kg, vancomycin at 20 mg/kg plus gentamicin at 1.5 mg/kg, ampicillin at 30 mg per rat per injection, and ampicillin at 30 mg per rat plus gentamicin at 1.5 mg/kg. Animals receive Daptomycin20 once daily; all other drugs are administered twice daily. Vancomycin and Daptomycin are given subcutaneously; ampicillin and gentamicin are given intramuscularly. Drugs are administered for up to 13 days.
References: [1]. Benson CA, et al. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987 Aug;20(2):191-6. [2]. Miniter PM, et al. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31(8):1199-203. [3]. Allen NE, et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC74557 PREX-in1 PREX-in1 is a specific small-molecule inhibitor of P-Rex1 and P-Rex2 Rac-GEF activity with IC50 of 4.5 uM (P-Rex1 DHPH Rac-GEF activity) in liposome-based GEF assay, inhibits P-Rex1 and P-Rex2 through their catalytic DH domain.
DC74555 GYS32661 GYS32661 (GYS 32661) is a potent Rac inhibitor capable of inhibiting both Rac1 and Rac1b, inhibited activated Rac1 with IC50 of 1.18 uM in in vitro pull-down assays.
DC74539 L557-0155 L557-0155 is a small molecule inhibitor of VSIG-8, prevents VSIG-8 binding to VISTA, promotes cytokine production and cell proliferation in PBMCs and suppresses melanoma growth.
DC74528 K284 K284 is a selective small molecule inhibitor of chitinase 3 like1 (CHI3L1) with strong binding affinity (Kd=-9.7 kcal·mol-1), inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals.
DC74225 YB-537 YB-537 (YB537) is a potent, highly specific quinone reductase 2 (QR2) inhibitor with IC50 of 3 nM, shows no activity against QR1 (IC50>10 uM).
DC74223 X-Neu5Ac X-Neu5Ac (sodium) is a substrate for chromogenic assay of neuraminidase activity in bacterial expression systems; with a Km of 0.89 mM for neuraminidase.
DC74218 UT-59 UT-59 is a specific inhibitor of cholesterol-sensing membrane protein Scap, binds to Scap's cholesterol-binding site, blocks SREBP activation and inhibits lipid synthesis.
DC74205 Tryptolinamide Tryptolinamide (TLAM) is a small-molecule compound that activates mitochondrial respiration in cybrids generated from patient-derived mitochondria and fibroblasts from patient-derived iPSCs, inhibits phosphofructokinase-1 (PFK1) with an ATP-uncompetitive
DC74203 TR-107 TR-107 (TR107) is a highly potent, selective and orally bioavailable small-molecule activator of the mitochondrial protease ClpP with EC50 of 140 nM, binds to purified ClpP with Kd value of 180 nM in surface plasmon resonance (SPR) measurement.
X